Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphomaBrian T. Hill,Yanwen Chen,Deepa Jagadeesh,Robert Dean,Omer Koc,Kirsten Boughan,Brenda Cooper,Brad Pohlman,Paolo Caimi,Mitchell R. SmithLeukemia & Lymphoma(2024)引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要